Broughton C M, Sherrington P, Pender N T, Clark R E
University Department of Haematology, Royal Liverpool University Hospital, United Kingdom.
Genes Chromosomes Cancer. 1997 Apr;18(4):292-8.
Following chemotherapy in chronic myeloid leukaemia (CML), some peripheral blood (PB) cells may be Philadelphia (Ph) chromosome negative. The BCR-ABL mRNA status of residual Ph+ progenitors is not known. We examined the BCR-ABL mRNA status of individual colony-forming-unit granulocyte-macrophage (CFU-GM) colonies derived from PB harvested following chemotherapy. Seven patients were treated with 200 mg/m2/day cytarabine and 20 mg/m2/day Idarubicin and followed by Lenograstim. PB collections commenced daily when the white blood cell count reached 0.6 x 10(9)/l and continued until at least 5 x 10(8)/kg nucleated cells were obtained. CD34+ cells, Ph status, and CFU-GM were estimated at each harvest. For each patient, up to 24 individual CFU-GM colonies were analysed for BCR-ABL status. Two cases were BCR-ABL negative on all colonies and completely Ph-, and another case was BCR-ABL positive in all colonies and completely Ph+. In contrast, in two patients all colonies were BCR-ABL negative, despite virtually complete Ph+ metaphases. The final assessible case had five of nine BCR-ABL negative colonies, despite 94% Ph+ metaphases. After chemotherapy priming, the PB may contain Ph+ CFU-GM that do not express BCR-ABL.
在慢性髓性白血病（CML）化疗后，一些外周血（PB）细胞可能为费城（Ph）染色体阴性。残留的Ph+祖细胞的BCR-ABL mRNA状态尚不清楚。我们检测了化疗后采集的外周血中单个集落形成单位粒细胞-巨噬细胞（CFU-GM）集落的BCR-ABL mRNA状态。7例患者接受了200mg/m²/天的阿糖胞苷和20mg/m²/天的伊达比星治疗，随后使用粒细胞集落刺激因子。当白细胞计数达到0.6×10⁹/L时开始每日采集外周血，并持续采集直至获得至少5×10⁸/kg有核细胞。每次采集时评估CD34+细胞、Ph状态和CFU-GM。对每位患者，分析多达24个单个CFU-GM集落的BCR-ABL状态。2例患者的所有集落均为BCR-ABL阴性且完全Ph-，另一例患者的所有集落均为BCR-ABL阳性且完全Ph+。相比之下，2例患者的所有集落均为BCR-ABL阴性，尽管几乎完全是Ph+中期。最后一例可评估的患者有9个集落中的5个为BCR-ABL阴性，尽管Ph+中期占94%。化疗预处理后，外周血中可能含有不表达BCR-ABL的Ph+CFU-GM。
